Develops blood-based cancer screening tests built on cell-free DNA methylation and machine learning. SimpleScreen CRC is its first FDA-approved product; listed on Nasdaq as FRNM in July 2026.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
Unsubscribe anytime. We never sell the list.